C16G2

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dental Caries

Conditions

Dental Caries

Trial Timeline

Jul 1, 2015 → Mar 1, 2016

NCT ID

NCT02509845

About C16G2

C16G2 is a phase 2 stage product being developed by Armata Pharmaceuticals for Dental Caries. The current trial status is completed. This product is registered under clinical trial identifier NCT02509845. Target conditions include Dental Caries.

What happened to similar drugs?

1 of 8 similar drugs in Dental Caries were approved

Approved (1) Terminated (0) Active (7)

✅2 mg nicotine gum + 4 mg nicotine gumJohnson & JohnsonApproved

🔄Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3

🔄Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3

🔄acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3

🔄Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3

🔄Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3

🔄Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02509845	Phase 2	Completed	Jul 1, 2015	Mar 1, 2016	Dental Caries
NCT02254993	Phase 2	Completed	Oct 1, 2014	Jul 1, 2015	Dental Caries

Competing Products

20 competing products in Dental Caries

See all competitors

Product	Company	Stage	Hype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tablet	Johnson & Johnson	Phase 3	40
Sodium Fluoride Dentifrice	Johnson & Johnson	Pre-clinical	26
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + Placebo	Johnson & Johnson	Phase 3	40
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + Placebo	Johnson & Johnson	Phase 2	35
2 mg nicotine gum + 4 mg nicotine gum	Johnson & Johnson	Approved	43
Acetaminophen ER + Placebo	Johnson & Johnson	Phase 2	35
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsule	Johnson & Johnson	Phase 3	40
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassium	Novartis	Phase 3	40
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	35
Pregabalin + Alprazolam + Placebo	Pfizer	Phase 2	35
Prototype (AN0128 Toothpaste)	Pfizer	Phase 1	29
PF-05089771 + PF-05089771 + PF-05089771 + Ibuprofen	Pfizer	Phase 2	35
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	35
PF-04531083 + PF-04531083 + Ibuprofen	Pfizer	Phase 2	27
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + Placebo	Bayer	Phase 3	37
XPF-001 + placebo	Xenon Pharmaceuticals	Phase 2	32
N1539 + placebo + N1539 + N1539 + Motrin	Alkermes	Phase 2	32
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placebo	Organon	Phase 3	34
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + Placebo	AFT Pharmaceuticals	Phase 2	17
Maxigesic 325 + Acetaminophen + Ibuprofen + Placebo	AFT Pharmaceuticals	Phase 3	30